Drug Trial Radar · NCT06553248
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 22, 2023
Primary completion
Nov 1, 2023
Study completion Nov 1, 2023
Sponsor
- Lead sponsor
- Gan and Lee Pharmaceuticals, USAIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of mutiple-dose GZR4 in subjects with type 2 diabetes
Conditions
- Diabetes
Interventions
GZR4Drug
Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
Insulin DegludecDrug
Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAETime frame: Baseline to Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals Co., Ltd
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.